DWA
ANIK icon

Dorsey Wright & Associates’s Anika Therapeutics ANIK Stock Holding History

Dorsey Wright & Associates’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-200
Closed -$11K – 271
2019
Q3 		$11K Buy
+200
New +$10.3K ﹤0.01% 207

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Dorsey Wright & Associates's ANIK Position: Q4 2019 in Review

Dorsey Wright & Associates sold out of Anika Therapeutics (ANIK) in Q4 2019, closing a stake of 200 shares — an estimated $11K sold.

Dorsey Wright & Associates first reported a position in ANIK in Q3 2019 and held it in 1 quarter. The position peaked at $11K in Q3 2019. 191 funds tracked by Wall St. Rank hold ANIK as of Q4 2019.

  • Dorsey Wright & Associates reported no remaining Anika Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Dorsey Wright & Associates sold 200 Anika Therapeutics shares in Q4 2019, an estimated $11K.
  • Dorsey Wright & Associates first reported a position in Anika Therapeutics in Q3 2019 and held it in 1 quarter.
  • Dorsey Wright & Associates's Anika Therapeutics position peaked at $11K in Q3 2019.
  • 191 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2019.

Based on Dorsey Wright & Associates's 13F filing for Q4 2019, filed 31 Jan 2020.